Call Now
DRUGART™.AI powers the discovery, characterization and optimization of drug biomolecules pre- and during development stages.
We serve our clients by providing unmatched intelligence on their drug targets pre- and during development –AND- pre- and during clinical trials.
Our technology has some of the best algorithms for preprocessing big metagenomic and genomic datasets. It can also process group and individual biological sequences.
We have converged bioinformatics, machine learning, deep learning and structural biology tools for biological molecules’ development.
We predict and engineer functional domains, active sites, protein-protein binding, peptide-ligand binding and perform other biological intelligence matrices.
We provide AI-backed services that enable robust identification and characterization of known and unknown biomolecules of healthcare importance
We algorithmically converge four (4) fields – bioinformatics, machine learning, deep learning and structural biology – to bypass extensive wet-lab processes in finding biomolecules of interest from various biological datasets
At a comfortable cost to our clients, our AI platform has configurations that can enable the engineering of biomolecules to meet specified requirements for different clinical outcomes
Although we have our proprietary biodata, we provide bioanalytic services based on client requirements, this includes exploring novelty model evaluations in concert with targeted disease
Our services offer the extensive convergence of tools that assure clients a level of success upfront bere the wet laboratory or other processes
Our journey started in 2020 to be at the forefront of the intersection between biology and AI for the human good. We want to contribute to the global healthcare industry by reducing the tedious and costly efforts needed to develop healthcare biomolecules and drive down costs for biopharmaceuticals development.
Collaborativeness
Inventiveness
Leadableness
Trustworthiness
© Avrobiomics. All Rights Reserved.